°¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå ¿¹Ãø(-2032³â) : °¨¿°Áõ À¯Çü, ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© ¹æ¹ý, À¯Åë ä³Î, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®
Infectious Disease Therapeutics Market Forecasts to 2032 - Global Analysis By Infection Type, Drug Class, Mode of Administration, Distribution Channel, End User and By Geography
»óǰÄÚµå : 1755939
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,673,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,177,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,681,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,253,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡ 1,352¾ï 5,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇϸç 2032³â¿¡´Â 2,064¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 6.23%ÀÔ´Ï´Ù.

°¨¿° Ä¡·áÁ¦¿¡´Â ¼¼±Õ, ¹ÙÀÌ·¯½º, °õÆÎÀÌ, ±â»ýÃæ¿¡ ÀÇÇÑ °¨¿°¿¡ ´ëóÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ Ä¡·áÁ¦°¡ Æ÷ÇԵ˴ϴÙ. Ç×»ýÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×Áø±ÕÁ¦, Ç×±â»ýÃæÁ¦´Â ÀÌ·¯ÇÑ Ä¡·áÁ¦ÀÇ ÇÑ ¿¹À̸ç, ¸ðµÎ ƯÁ¤ º´¿ø±Õ¿¡ ÀÛ¿ëÇÏ¿© °¨¿°À» ±ÙÀýÇϰųª È®»êÀ» ¸·´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¾àÁ¦ ³»¼º±Õ°ú °¨¿°ÁõÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú ¹é½Å °³¹ßÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× ºÐÀÚÁø´ÜÇÐÀÇ ¹ß´Þ·Î º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ °³º° Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¹ÙÀÌ·¯½º¼º °£¿°(BÇü ¹× CÇü)Àº 2022³â 130¸¸ ¸íÀÇ »ç¸ÁÀÚ¸¦ ³»¸ç °áÇÙÀ» ³Ñ¾î¼¹½À´Ï´Ù. ¶ÇÇÑ 2020³â¿¡´Â ¸»¶ó¸®¾Æ, °áÇÙ, ¿¡ÀÌÁîÀÇ ¿¬°£ »ç¸ÁÀÚ ¼ö¸¦ ÇÕÄ£ °Íº¸´Ù ´õ ¸¹À» °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, °­·ÂÇÑ °¨¿°º´ Ä¡·áÁ¦°¡ ½Ã±ÞÈ÷ ÇÊ¿äÇÔÀ» ¿©½ÇÈ÷ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

°¨¿°¼º Áúȯ ¹ßº´·ü Áõ°¡

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ã߻꿡 µû¸£¸é HIV/AIDS, °£¿°, ¸»¶ó¸®¾Æ, °áÇÙÀ» ÇÕÄ¡¸é ¸Å³â ¼ö¹é¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â ¸Å³â ¼ö¹é¸¸ ¸íÀÌ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛ ¶ÇÇÑ COVID-19¿Í °°Àº Àü¿°º´À̳ª µ¶°¨°ú °°Àº °èÀý¼º ÁúȯÀ¸·Î ÀÎÇØ ½ºÆ®·¹½º¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ç¸Á·üÀ» ³·Ãß°í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇÑ È¿À²ÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺Àº ÀÌ·¯ÇÑ Áö¼ÓÀû À̰í Áõ°¡ÇÏ´Â ºÎ´ã¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù.

°í°¡ÀÇ ÀÓ»ó½ÃÇè ¹× ÀǾàǰ °³¹ß

°¨¿°º´ÀÇ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§Çؼ­´Â ÀüÀÓ»ó ¿¬±¸, ¿©·¯ ´Ü°èÀÇ ÀÓ»ó½ÃÇè, ÁýÁßÀûÀÎ ¿¬±¸°³¹ßÀÌ ¸ðµÎ ÇÊ¿äÇϸç, ÀÌ ¸ðµç °úÁ¤¿¡´Â ºñ¿ë°ú ½Ã°£ÀÌ ¼Ò¿äµË´Ï´Ù. ÇϳªÀÇ ÀǾàǰÀ» ½ÃÀå¿¡ Ãâ½ÃÇÏ·Á¸é 10³â ÀÌ»óÀÇ ½Ã°£°ú ¼ö½Ê¾ï ´Þ·¯ÀÇ ºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. Á¦¾àȸ»çµéÀº ÁÖ·Î Àú¼ÒµæÃþÀÌ ÁÖ·Î ¾Î°í ÀÖ´Â °¨¿°¼º Áúȯ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ýÀ» Ãß±¸ÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ¾ö°ÝÇÑ ¾ÈÀü¼º ¹× À¯È¿¼º ¿ä°ÇÀÌ °³¹ß ºñ¿ë°ú °³¹ß ±â°£À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

»ý¹°¹æ¾î ¹× ÆÒµ¥¹Í ´ëÀÀ¿¡ ´ëÇÑ ÁöÃâ Áõ°¡

°¢±¹ Á¤ºÎ¿Í ±¹Á¦±â±¸´Â ½ÅÁ¾ °¨¿°º´ À§Çù¿¡ ´ëÇÑ ½Å¼ÓÇÑ ´ëÀÀ Ç÷§Æû °³¹ß, ¿¬±¸°³¹ß ¿ª·® °­È­, Ç×¹ÙÀÌ·¯½ºÁ¦ ÃàÀû¿¡ ÁßÁ¡À» µÎ°í º¸°Ç¾Èº¸¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀǾàǰ °³¹ßÀÚµéÀº WHOÀÇ R&D û»çÁø(R&D Blueprint), BARDA(Biomedical Advanced Research and Development Authority), CEPI(Coalition for Epidemic Preparedness Innovations)¿Í °°Àº ÇÁ·Î±×·¥¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. Preparedness Innovations) µîÀÇ ÇÁ·Î±×·¥À» ÅëÇØ ¸·´ëÇÑ ÀÚ±Ý Áö¿ø°ú °øµ¿ ¿¬±¸ ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

º´¿ø±ÕÀÇ ±Þ¼ÓÇÑ ÁøÈ­¿Í º¯ÀÌ

¹ÚÅ׸®¾Æ¿Í ¹ÙÀÌ·¯½º´Â ³ôÀº ÀûÀÀ·Â°ú ºü¸¥ º¯ÀÌ·Î ÀÎÇØ ¶§¶§·Î ÇöÀçÀÇ Ä¡·á¹ýÀÌ È¿°ú°¡ ¾øÀ» ¼ö ÀÖ½À´Ï´Ù. ¿À¹Í·Ð°ú °°Àº »õ·Î¿î º¯Á¾ COVID-19ÀÇ ÃâÇöÀº º´¿øÃ¼°¡ ¾ó¸¶³ª ºü¸£°Ô º¯È­ÇÏ°í ¹é½Å°ú Ä¡·áÁ¦ °³¹ßÀ» ´É°¡ÇÒ ¼ö ÀÖ´ÂÁö¸¦ º¸¿©ÁÖ¾ú½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¿¹Ãø ºÒ°¡´É¼ºÀº Àå±âÀûÀÎ Ä¡·á È¿°ú¸¦ À§ÇùÇϰí, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ, ÀçÅõÀÚ, Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ¾÷µ¥ÀÌÆ®°¡ ÇÊ¿äÇϸç, ÀÌ´Â Á¦¾àȸ»ç¿¡°Ô °³¹ß À§Çè°ú ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19 ÆÒµ¥¹ÍÀº ¼¼°è º¸°ÇÀÇ ¿ì¼±¼øÀ§¸¦ ¹Ù²Ù°í, ÀÚ±ÝÀ» ´Ã¸®°í, ±â¼ú Çõ½ÅÀ» °¡¼ÓÈ­ÇßÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ °¨¿°º´ Ä¡·áÁ¦ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±× °á°ú, mRNA ±â¼ú, ´ÜÀÏ Å¬·Ð Ç×ü, Ç×¹ÙÀÌ·¯½ºÁ¦¿¡ ´ëÇÑ Àü·Ê ¾ø´Â ÅõÀÚ°¡ ÀÌ·ç¾îÁ³½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÌ ½Å¼Ó ½ÂÀÎ °æ·Î¸¦ äÅÃÇÏ°í ¹Ì·¡ ÀǾàǰ °³¹ßÀÇ »õ·Î¿î ±âÁØÀ» ¼³Á¤ÇÔÀ¸·Î½á º¸´Ù ½Å¼ÓÇÑ Ä¡·á¹ý °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÆÒµ¥¹ÍÀº ¶ÇÇÑ Áúº´ °ü¸®¿¡¼­ ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ °Ç°­ÀÇ ¿ªÇÒÀ» Áõ´ë½Ã۰í, ±¹°æÀ» ÃÊ¿ùÇÑ Çù·ÂÀ» ÃËÁøÇϰí, °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀ» ³ô¿´½À´Ï´Ù.

¿¹Ãø ±â°£ Áß ¹é½Å ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¹Ãø ±â°£ Áß ¹é½Å ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°è ÀÎÁöµµ Çâ»ó, ¹é½Å Á¢Á¾ Ä·ÆäÀο¡ ´ëÇÑ Á¤ºÎÀÇ ±¤¹üÀ§ÇÑ Áö¿ø, ±¤¹üÀ§ÇÑ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÌ ÀÌ·¯ÇÑ ¿ìÀ§ÀÇ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ¹é½ÅÀº ÀÌÁ¦ ¿¹¹æÀû ¹æ¾î»Ó¸¸ ¾Æ´Ï¶ó Àü¿°º´°ú Àü¿°º´À» °ü¸®Çϱâ À§ÇÑ Àü·«Àû ÅøÀÌ µÇ¾ú½À´Ï´Ù. ¼ºÀΰú ¼Ò¾Æ Áý´Ü ¸ðµÎ¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ°í ÀÖÀ¸¸ç, mRNA ¹× À¯ÀüÀÚ ÀçÁ¶ÇÕ ±â¼úÀÇ ¹ßÀü°ú °áÇÕÇÏ¿© ½ÃÀå ¸®´õ·Î¼­ÀÇ ÀÔÁö¸¦ °­È­ÇÏ°í ¼±Áø±¹°ú ½ÅÈï ±¹°¡ ¸ðµÎ¿¡¼­ ²ÙÁØÇÑ ¼ºÀåÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â ºñ°­ ºÎ¹®ÀÔ´Ï´Ù.

¿¹Ãø ±â°£ Áß ºñ°æ±¸ ºÎ¹®Àº °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ƯÈ÷ ÀþÀº Ãþ°ú ³ë³âÃþ¿¡¼­ ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ºñħ½ÀÀû ºñħ½ÀÀû ¾à¹°Àü´Þ ±â¼ú¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ºñ°­ Á¦Á¦´Â ¼ÒÈ­°ü ¹× ù ¹øÂ° Åë°ú ´ë»ç¸¦ ÇÇÇÔÀ¸·Î½á ºü¸¥ ¾àÈ¿ ¹ßÇöÀ» ½ÇÇöÇϹǷΠÀÀ±Þ Ä¡·á ¹× ¿¹¹æÁ¢Á¾¿¡ ÀûÇÕÇÕ´Ï´Ù. ÃÖ±Ù Ç×¹ÙÀÌ·¯½º ½ºÇÁ·¹ÀÌ¿Í ºñ°­ ¹é½ÅÀÇ ¹ßÀüÀ¸·Î ÀÌ ½ÃÀå ºÎ¹®¿¡ ´ëÇÑ °ü½É°ú ÅõÀÚ°¡ Áõ°¡Çϸ鼭 ÇâÈÄ ¼ºÀå¿¡ Áß¿äÇÑ ºÐ¾ß·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À² Áö¿ª:

¿¹Ãø ±â°£ Áß ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀº Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ, ³ôÀº ÀÇ·áºñ, ÃÖ°í ¼öÁØÀÇ »ý¸í°øÇÐ ¹× Á¦¾à ±â¾÷ÀÇ ÅºÅºÇÑ ÀÔÁö¸¦ ¹ÙÅÁÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº °­·ÂÇÑ R&D ¿ª·®, ÃÖ÷´Ü Ä¡·á¹ýÀÇ ±¤¹üÀ§ÇÑ »ç¿ë, FDAÀÇ ½Å¼ÓÇÑ ½ÂÀÎ ÀýÂ÷ µî °í¹«ÀûÀÎ ±ÔÁ¦ ȯ°æÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °£¿°, HIV, µ¶°¨ µî °¨¿°¼º ÁúȯÀÇ ³ôÀº À¯º´·ü, Á¤ºÎ Áö¿ø ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎ ¹× °øÁߺ¸°Ç Ä·ÆäÀεµ ½ÃÀå ¿ìÀ§¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¨¿°¼º Áúȯ ¹ßº´·ü Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ ¼ºÀå, ÀǾàǰ °³¹ß ¹× ÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ÅõÀÚ Áõ°¡°¡ ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹, Àεµ, µ¿³²¾Æ½Ã¾Æ µîÀÇ ±¹°¡¿¡¼­´Â Àα¸°¡ Áõ°¡Çϰí Áúº´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó º¸´Ù Àú·ÅÇϰí È¿À²ÀûÀÎ Ä¡·á¹ýÀ» ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¿ª »ý¸í°øÇÐ ±â¾÷ÀÇ ¼³¸³, Áø´Ü ±â¼úÀÇ ¹ßÀü, Á¤ºÎ ÁÖµµÀÇ ¹é½Å Á¢Á¾ Ä·ÆäÀÎ µîÀÌ Ä¡·áÁ¦ÀÇ º¸±ÞÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀº ÀÌ Áö¿ªÀÇ ±ÔÁ¦ ȯ°æÀÇ º¯È­µµ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : °¨¿°Áõ À¯Çüº°

Á¦6Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

Á¦7Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : Åõ¿© ¹æ¹ýº°

Á¦8Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°

Á¦9Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ °¨¿°Áõ Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä ¹ßÀü

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Infectious Disease Therapeutics Market is accounted for $135.25 billion in 2025 and is expected to reach $206.49 billion by 2032 growing at a CAGR of 6.23% during the forecast period. Infectious disease therapeutics encompasses a broad range of treatments aimed at combating infections caused by bacteria, viruses, fungi, and parasites. Antibiotics, antivirals, antifungals, and antiparasitic medications are examples of these therapeutics; they all work against particular pathogens to eradicate or stop the spread of infection. The creation of innovative treatments and vaccines has become more and more important as drug-resistant bacteria and infectious diseases have increased. More accurate, efficient, and individualized treatments are now possible owing to developments in biotechnology and molecular diagnostics.

According to the World Health Organization, viral hepatitis (B and C) caused 1.3 million deaths in 2022, surpassing tuberculosis, and is projected to exceed the combined annual fatalities of malaria, TB, and AIDS by 2040-a stark indicator of the urgent need for potent infectious disease therapeutics.

Market Dynamics:

Driver:

Increasing infectious disease incidence

One of the biggest health burdens in the world is still the prevalence of infectious diseases. WHO estimates that HIV/AIDS, hepatitis, malaria, and tuberculosis together account for millions of deaths each year, particularly in low- and middle-income nations. Healthcare systems are also still under stress from outbreaks like COVID-19 and seasonal illnesses like influenza. Additionally, the need for efficient treatments to lower mortality and enhance patient outcomes is sustained by this ongoing and increasing burden.

Restraint:

Expensive clinical trials and drug development

Preclinical research, several stages of clinical trials, and intensive R&D are all necessary to develop new treatments for infectious diseases, and they are all costly and time-consuming. To get a single drug to market, it can take more than ten years and cost billions of dollars. Pharmaceutical companies are discouraged from pursuing new treatments for infectious diseases that primarily affect low-income populations because the return on investment may be low. Furthermore, raising development costs and timelines are regulatory bodies' strict safety and efficacy requirements.

Opportunity:

Increasing spending on biodefense and pandemic preparedness

Governments and international organizations are investing more in health security, with a particular emphasis on developing rapid-response platforms for emerging infectious threats, improving R&D capabilities, and accumulating antivirals. Moreover, drug developers can find substantial funding and collaboration opportunities through programs like WHO's R&D Blueprint, BARDA (Biomedical Advanced Research and Development Authority), and CEPI (Coalition for Epidemic Preparedness Innovations).

Threat:

Rapid pathogen evolution and mutation

Due to their high degree of adaptability and rapid mutation, bacteria and viruses can occasionally make current treatments ineffective. The appearance of novel COVID-19 variations, like Omicron, showed how quickly pathogens can change and surpass the development of vaccines and treatments. Additionally, long-term therapeutic efficacy is threatened by this unpredictability, necessitating ongoing monitoring, reinvestment, and treatment protocol updates, which raises development risks and costs for pharmaceutical companies.

Covid-19 Impact:

The COVID-19 pandemic changed the priorities of global health, boosted funding, and accelerated innovation, all of which had a substantial impact on the infectious disease therapeutics market. It highlighted the urgent need for quick therapeutic development, which resulted in previously unheard-of investments in mRNA technology, monoclonal antibodies, and antiviral medications. Faster treatment deployment was made possible by regulatory bodies' adoption of expedited approval pathways, which established a new standard for future drug development. The pandemic also increased the role of telemedicine and digital health in disease management, promoted cross-border cooperation, and raised public awareness of infectious diseases.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period. Increased global awareness, extensive government support for vaccination campaigns, and extensive immunization programs are the main causes of this dominance. Vaccines are now a strategic tool for managing pandemics and epidemics in addition to providing preventive protection. Their widespread application in both adult and pediatric populations, combined with ongoing developments in mRNA and recombinant technologies, has strengthened their position as market leaders and guaranteed steady growth in both developed and emerging nations.

The intranasal segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the intranasal segment is predicted to witness the highest growth rate. This expansion is fueled by a growing desire, particularly among young and elderly populations, for needle-free, non-invasive drug delivery techniques that improve patient compliance. Moreover, intranasal formulations are perfect for emergency treatments and vaccinations because they provide a quick onset of action by avoiding the gastrointestinal tract and first-pass metabolism. Recent advancements in antiviral sprays and intranasal vaccines, increased interest in and investment in this market segment and established it as a crucial area for future growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, propelled by its sophisticated healthcare system, substantial healthcare expenditures, and robust presence of top biotechnology and pharmaceutical firms. The area gains from strong R&D capacities, broad use of cutting-edge treatment alternatives, and encouraging regulatory environments such as the FDA's expedited approval processes. Additionally, the high incidence of infectious diseases like hepatitis, HIV, and influenza, as well as government-sponsored immunization campaigns and public health campaigns, also play a big role in market dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rising infectious disease rates, growing healthcare infrastructure, and rising public and private investments in drug development and medical research are the main drivers of this growth. Because of their expanding populations and increased awareness of disease, countries like China, India, and Southeast Asia are seeking more affordable and efficient treatments. Furthermore, the launch of regional biotech companies, advancements in diagnostic technology and government-led vaccination campaigns are speeding up the adoption of treatments. The rapidly expanding market is further supported by the region's changing regulatory environment.

Key players in the market

Some of the key players in Infectious Disease Therapeutics Market include BioCryst Pharmaceuticals Inc. , GlaxoSmithKline plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Gilead Sciences Inc., AstraZeneca Inc, Merck & Co., Inc. , Bayer AG, Amgen Inc., Novartis AG, Bristol-Myers Squibb (BMS), Abbott Laboratories, Pfizer Inc. , Sanofi , Janssen Pharmaceutical Inc., Takeda Pharmaceutical and Sandoz International GmbH.

Key Developments:

In June 2025, BioCryst Pharmaceuticals, Inc. announced the extension of its consulting agreement with former Chief Financial Officer Anthony Doyle. This information was disclosed in a recent SEC filing. The company, with a market capitalization of $2.34 billion, has shown impressive momentum with a 66% return over the past year and revenue of $503 million in the last twelve months.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In January 2025, GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage Biopharmaceutical Company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.

Infection Types Covered:

Drug Classes Covered:

Mode of Administrations Covered:

Distribution Channels Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Infectious Disease Therapeutics Market, By Infection Type

6 Global Infectious Disease Therapeutics Market, By Drug Class

7 Global Infectious Disease Therapeutics Market, By Mode of Administration

8 Global Infectious Disease Therapeutics Market, By Distribution Channel

9 Global Infectious Disease Therapeutics Market, By End User

10 Global Infectious Disease Therapeutics Market, By Geography

11 Key Developments

12 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â